As Court Battle Rages, Pfizer's Celebrex Sales Soar

Law360, New York (July 13, 2007, 12:00 AM EDT) -- In its annual financial statement to the U.S. Securities and Exchange Commission, drug maker Pfizer Inc. warned that “continuing concern” about the safety of its anti-inflammatory drug Celebrex might limit the company's ability to increase sales.

The concerns prompted the drug maker to embark on a direct-to-consumer TV ad campaign this April, which was “helping to stimulate patient interest,” the company told the SEC this week, and had contributed to total worldwide sales of $1.1 billion in the first half of 2007.

In Pfizer's statement to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.